

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Nursing Research; Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Name of Committee: National Institute of Nursing Research Initial Review Group.

Date: February 26–27, 1998.

Time: 8:30 a.m. until adjournment.

Place: Holiday Inn Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, Maryland 20815.

Contact Person: Mary Stephens-Frazier, Ph.D., Building 45, Room 3AN-18, 45 Center Drive, Bethesda, MD 20892, (301) 594-5971.

Purpose/Agenda: To review and evaluate grant applications.

This meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program No. 93.361, Nursing Research, National Institutes of Health)

Dated: January 6, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-906 Filed 1-13-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Warren Grant Magnuson Clinical Center; Meeting of the Board of Governors

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the Board of Governors of the Warren Grant Magnuson Clinical Center, January 23, 1998. The Board of Governors will meet at the National Institutes of Health, Clinical Center (Building 10), Medical Board Room (2C116), 9000 Rockville Pike, Bethesda, Maryland, from 9:00 a.m. until approximately 12:00 p.m.

The meeting will be open to the public from 9:00 a.m. to 11:30 a.m. and will include review of the minutes of the December 1, 1997 Executive Committee meeting, membership rotation schedule, updates on the

Budget and Strategic Planning, and the Director's Annual Report.

In accordance with the provisions set forth in section 552b(c)(6) of Title 5, U.S.C. and section 10(d) of Public Law 92-463, the meeting will be closed to the public from approximately 11:30 a.m. to adjournment for discussion of personnel qualifications and performance of the Director, Clinical Center, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Attendance by the public will be limited to space available.

For further information, contact Ms. Maggi Stakem, Office of the Director, Warren Grant Magnuson Clinical Center, Building 10, Room 2C146, Bethesda, Maryland 20892, (301) 496-4114.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Stakem in advance of the meeting.

This notice is being published less than fifteen days prior to this meeting due to scheduling conflicts.

Dated: January 7, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-893 Filed 1-13-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

National Toxicology Program; Board of Scientific Counselors' Meeting

Pursuant to Public Law 92-463, notice is hereby given of a meeting of the National Toxicology Program (NTP) Board of Scientific Counselors, U.S. Public Health Service, in the Conference Center, Building 101, South Campus, National Institute of Environmental Health Sciences (NIEHS), 111 Alexander Drive, Research Triangle Park, North Carolina, on February 5 and 6, 1998.

Agenda

The meeting will be open to the public from 8:45 a.m. to 4:00 p.m. on February 5, and from 8:45 a.m. to adjournment on February 6, with attendance limited only by space available. The primary agenda topic on February 5 will be a comprehensive evaluation of the strategies for use of transgenic mouse models in bioassays for carcinogenesis. Included will be an introduction, history and rationale for using transgenic animals to identify

carcinogens, sharing of results from three mouse models—p53^{def}, Tg.AC, and *rasH2*—, NTP strategies for evaluating models, utility of transgenic model results for risk assessment, and regulatory agency perspectives. There are four issues that the Board will be asked to advise the NTP on, being: (1) Is the NTP approach to evaluation and validation of transgenic models for use in cancer bioassays sufficient and appropriate?; (2) How can existing models be best utilized? What are their limitations?; (3) What new models are needed, i.e., should the NTP seek to develop organ-specific tumor models; and (4) Are the scientific needs of regulatory agencies being adequately addressed? Background materials pertaining to the evaluation of transgenic models will be available on request from the Executive Secretary after January 12, 1998.

Among several agenda topics on February 6 will be a discussion of and opportunity for public comment on chemicals nominated for NTP studies that were reviewed by the NTP Interagency Committee for Chemical Evaluation and Coordination on August 15, 1997, and December 11, 1997. The Committee recommended nine chemicals and four mixtures for toxicological studies, recommended four chemicals be deferred for additional information, and recommended six chemicals not be studied. The chemicals/classes with CAS Nos. in parentheses are—*Recommended for Study*: (1) 2-Acetylpyridine (1122-62-9); (2) Asphalt Fumes (8052-42-4); (3) 2-Chloropyridine (109-09-1); (4) Comfrey (72698-57-8) with Symphytine (22571-95-5); (5) Glycoluril (496-46-8); (6) Goldenseal (—) containing Berberine (2086-83-1) and Hydrastine (118-08-1); (7) Luminol (o-Aminophthalic Hydrazide) (521-31-3); (8) 4-Methoxy-N-methyl-1,8-naphthalimide (3271-05-4); (9) Myristicin (607-91-0); (10) 7-(2H-Naphthol[1,2-d] triazol-2-yl)-3-phenylcoumarin; (11) Orphanic Acid (88-21-1); (12) Phenothiazine (92-84-2); and (13) Saw Palmetto containing β -Sitosterol (83-46-5). The chemicals for which *No Study is Recommended* are: (1) *trans*-1,4-Dichloro-2-butene; (2) Dicyclopentadiene (77-73-6); (3) C.I. Direct Black 80 (8003-69-8); (4) Ethyl Cyanoacrylate (7085-85-0); (5) Isoamyl Acetate; and (6) 2,4,6-Tribromophenol. *Chemicals Deferred for Additional Information* are: (1) 3-Amino-5-mercapto-1,2,4-triazole (16691-43-3); (2) Diethylamine (109-89-7); (3) Isopropylamine (75-31-0); and (4) Triethylamine (121-44-8).

Also, on February 6 will be reports of recent meetings of the Report on Carcinogens and Technical Reports Review Subcommittees. The Board will review concept proposals on (1) genetic susceptibility of the pregastrulation embryo to environmental exposures, (2) molecular detection of aneuploidy in rodent germ cells, and (3) pathology support for the National Toxicology Program.

Public Input Encouraged

In order to facilitate planning for the meeting, persons wanting to make a formal presentation during the public comment period must notify the Executive Secretary, Dr. Larry G. Hart, P.O. Box 12233, Research Triangle Park, NC 27709 (telephone 919/541-3971; FAX 919/541-0295; or email at hart@niehs.nih.gov) by no later than February 2, 1997, and, if possible, provide a written copy in advance of the meeting. Written statements should supplement and may expand on the oral presentation, or may be submitted in lieu of an oral presentation, and should be received by February 2 so copies can be made for distribution to Subcommittee members, staff, and the public. Oral presentations should be limited to no more than five minutes.

The Executive Secretary will furnish agenda and a roster of Board members and ad hoc expert reviewers prior to the meeting. Summary minutes subsequent to the meeting will be available upon request.

Dated: January 7, 1998.

Samuel H. Wilson,

Deputy Director, National Toxicology Program.

[FR Doc. 98-901 Filed 1-13-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

Centers for Disease Control and Prevention; Statement of Organization, Functions, and Delegations of Authority

Part C (Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772-76, dated October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as amended most recently at 62 FR 56197, dated October 29, 1997) is amended to reflect the reorganization of the Office of Equal

Employment Opportunity, Centers for Disease Control and Prevention.

Section C-B, Organization and Functions, is hereby amended as follows:

After the title *Office of Equal Employment Opportunity (CA9)*, delete the functional statement and substitute the following:

The Office of Equal Employment Opportunity (OEEO) is located in the Office of the Director, Centers for Disease Control and Prevention (CDC). The Director, OEEO, serves as the principal advisor to the Director, CDC, on all equal employment opportunity matters. The Office: (1) Develops and recommends for adoption CDC-wide EEO policies, goals, and priorities to carry out the directives of the U.S. Office of Personnel Management, U.S. Equal Employment Opportunity Commission, and Department of Health and Human Services (DHHS) equal employment opportunity policies and requirements that are mandated by Title VII, Civil Rights Act of 1964; Age Discrimination in Employment Act (ADEA); Rehabilitation Act of 1973; Civil Service Reform Act; 29 CFR 1614, Federal Sector Equal Employment Opportunity; Executive Order 11478, Equal Employment Opportunity in the Federal Government; (2) provides leadership, direction, and technical guidance to CDC EEO managers and staff for the development of comprehensive EEO programs and plans; (3) coordinates and evaluates agency EEO operations and plans, including affirmative action; (4) develops plans, programs, and procedures to assure the prompt receipt, investigation, and resolution of complaints of alleged discrimination by reason of race, sex, age, religion, national origin, handicap, or by reason of reprisal or retaliation; (5) coordinates the development of comprehensive special emphasis programs to assure full recognition of the needs of women, minorities, and the handicapped in hiring and employment; (6) identifies needs for EEO functions of within CDC and assures the development of a training curriculum in EEO for all CDC supervisory personnel; (7) prepares, or coordinates the preparation of, reports and analyses designed to reflect the status of employment of women and minorities at CDC and maintains liaison with DHHS and other organizations concerned with equal employment opportunity; (8) ensures effective coordination of EEO activities with CDC personnel and training programs, and with CDC Centers/Institute/Offices (CIOs) manpower planning and support programs in the health professions; (9)

develops a system of structured reviews and evaluations of CDC EEO activities to assure effective operations and accountability, including the Department's Major Initiatives Traction System for EEO; (10) assists in assuring the adequate allocation of resources for EEO including the establishment of guidelines for recruiting, selection, and training of agency EEO personnel; (11) develops and directs research and evaluation studies to focus on, and improve the effectiveness of, EEO program activities; (12) provides direct support for EEO program activities in CDC.

Office of the Director (CA91). Plans and directs the activities of OEEO.

Division of Affirmative Action (CA92).

(1) Manages the planning and monitoring of CDC's affirmative action activities; (2) develops and recommends CDC policies regarding affirmative action planning and monitoring; (3) develops and issues guidelines regarding the scope of, and the process for, developing CDC's Affirmative Action Plan (AAP), including establishing goals and timetables, developing planning methods, and preparing work force analyses; (4) coordinates the development and preparation of the CDC-wide AAP and recommends to the Director, OEEO, approval or rejection of affirmative action plans for CDC components; (5) reviews and makes recommendations to the Director, OEEO, regarding the appropriateness of items submitted by CIOs; (6) monitors and evaluates the implementation of the affirmative action program by collecting and analyzing data, reviewing periodic written reports from CIOs, and conducting spot-check reviews of subordinate level plans and programs; (7) provides training and technical assistance on affirmative action issues and concerns to managers and EEO officials throughout CDC; (8) provides CDC liaison with DHHS, other Federal agencies, community groups, and professional associations and organizations regarding affirmative action activities at CDC; (9) coordinates CDC affirmative action efforts with related Department activities in personnel, career development, training, and health manpower planning.

Division of Complaints Management and Adjudication (CA93).

(1) Conducts the discrimination complaints process for all CDC civilian and Commissioned Corps personnel; (2) issues operating policies and guidelines relative to discrimination complaint procedures; (3) monitors complaints of discrimination to detect indications of discriminatory patterns and practices; (4) prepares final decisions on all